Ocrelizumab: First Global Approval

Drugs
James E Frampton

Abstract

Ocrelizumab (Ocrevus™) is a humanised anti-CD20 monoclonal antibody that has been developed by Genentech, Inc. (a subsidiary of Roche) for the treatment of multiple sclerosis (MS). The drug is designed to deplete B cells, which play an important role in the pathogenesis of MS. In March 2017, ocrelizumab was approved in the USA for the treatment of patients with relapsing or primary progressive forms of MS; currently, it is awaiting approval in the EU for the same indications. This article summarizes the milestones in the development of ocrelizumab leading to its first global approval for the treatment of MS.

References

Jan 21, 2016·Therapeutic Advances in Neurological Disorders·Per Soelberg Sorensen, Morten Blinkenberg
Dec 22, 2016·The New England Journal of Medicine·Stephen L HauserUNKNOWN OPERA I and OPERA II Clinical Investigators
Dec 22, 2016·The New England Journal of Medicine·Xavier MontalbanUNKNOWN ORATORIO Clinical Investigators

❮ Previous
Next ❯

Citations

Aug 2, 2018·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Vrushali MangaleThomas E Lane
Sep 28, 2018·Neurology. Neuroimmunology and Neuroinflammation·Andrea MarcinnòAntonio Bertolotto
Jul 28, 2020·Reviews in the Neurosciences·Berenice Anabel SilvaCarina Cintia Ferrari
Apr 22, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Esther S FrischMartin S Weber
Aug 8, 2021·International Journal of Environmental Research and Public Health·Gianmarco AbbadessaSimona Bonavita

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Xavier MontalbanJerry S Wolinsky
The New England Journal of Medicine
Christian Schoergenhofer, Bernd Jilma
The New England Journal of Medicine
Stephen L HauserLudwig Kappos
The New England Journal of Medicine
Florian DeisenhammerHarald Hegen
© 2022 Meta ULC. All rights reserved